Drugs / CD8-Positive T-Lymphocyte
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03318900 | Sep 2018 → Dec 2023 | ovarian carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD8-Positive T-Lymphocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03318900 ↗ |
| Modality | Cell therapy | “adoptively transferred central memory-type CTL targeting ovarian cancer antigens” NCT03318900 ↗ |
| Route | Intravenous | “Given IV” NCT03318900 ↗ |